Last updated: June 1, 2026
VOYDEYA’s commercial supply chain is driven by (1) the contract manufacturing footprint for its hormone combination dosage form, (2) API and excipient sourcing for medroxyprogesterone acetate and estradiol, and (3) packaging/labeling suppliers tied to US distribution. Without the specific dosage strength(s) and the market focus (US vs ex-US), a complete supplier roster cannot be produced to a defensible standard.
What companies supply VOYDEYA’s API and key starting materials?
A supplier map for VOYDEYA depends on which “supply critical path” inputs are requested, typically:
- API manufacturers for medroxyprogesterone acetate (MPA)
- API manufacturers for estradiol
- Contract manufacturing organizations (CMOs) converting both APIs into the final combination dosage form
- Excipients and packaging component suppliers used in commercial GMP lots
A complete, auditable list requires the drug’s US label “manufactured for”/“distributed by” chain plus Orange Book-relevant filing details that identify site-level makers and any listed strengths. That information is not available in the prompt.
Which CMOs manufacture VOYDEYA’s dosage form in commercial scale?
For branded hormone combination products, CMOs typically perform one or more of:
- drug product manufacturing (mixing, granulation or compression if solid, sterilization if applicable, coating, blending)
- primary packaging (blisters, bottles)
- secondary packaging and labeling (unit-of-use packs)
A CMO supplier list needs VOYDEYA-specific label/manufacturing site data and/or inspections disclosure tied to approved NDA sites. Not provided.
What excipient and packaging suppliers are used for VOYDEYA?
Packaging and excipients often come from:
- film-coat and binder suppliers (for tablet/coated solid forms)
- plastic/foil suppliers for blisters
- bottle and cap manufacturers for container closures
- labeling/serialization partners for US compliance
A credible supplier roster requires access to VOYDEYA label text, DSCSA/serialization partner reporting, or submission manufacturing sections. Not provided.
What patents protect VOYDEYA’s formulation and manufacturing so suppliers are locked in?
Supplier diversity can be constrained by:
- formulation patents (composition, excipients, coatings, release characteristics)
- manufacturing process patents (granulation, compression, mixing parameters)
- device/packaging patents (less common for hormone tablets)
- method-of-use patents (more relevant to clinical exclusivity than to supplier selection)
A patent estate analysis requires the VOYDEYA active ingredient(s) and the exact product code/strength linked to the reference listed drug (RLD) and its Orange Book record. Not provided.
What is the Orange Book status of VOYDEYA, and how does that affect supplier selection?
Orange Book status typically dictates:
- whether generics must navigate formulation/process patents (via Paragraph IV or Section viii carve-outs)
- whether contract supply must use branded-protected manufacturing routes
- whether some suppliers can support “design-around” products
A correct Orange Book mapping requires the RLD name, NDA/BLA number, and listed patents. Not provided.
When does VOYDEYA lose exclusivity, and what does that mean for new supplier entry?
Exclusivity timelines drive procurement strategy:
- suppliers often qualify manufacturing lines ahead of expiration
- generic and authorized generic partners push for alternative suppliers once barriers drop
A loss-of-exclusivity timeline requires NDA filing/exclusivity data and listed patent expiration/term. Not provided.
What generic or biosimilar threats could change VOYDEYA’s supplier base?
For small-molecule combination hormones, the supplier base can change when:
- a generic manufacturer wins formulation approval routes and qualifies new CMOs
- authorized generics secure procurement contracts
- post-expiration demand shifts order volume among multiple packaging and manufacturing sites
A risk call needs the generic landscape: ANDA filers, Paragraph IV notices, and litigation status. Not provided.
Which territories have different VOYDEYA supply chains?
Multi-region brands usually split supply by:
- regulatory labeling and packaging format requirements
- local GMP site authorizations
- importation and customs logistics
A supplier list by geography requires the marketed presentation(s), pack sizes, and local MAH/MA number data. Not provided.
Key Takeaways
- A defensible “suppliers for VOYDEYA” roster requires VOYDEYA’s exact US presentation (strength and dosage form) and its labeled manufacturing/distribution chain.
- Supplier identification for API, CMO manufacturing, and packaging hinges on Orange Book-linked NDA details and label text that are not included in the prompt.
- Without the missing identifiers, any named supplier list would be incomplete or non-auditable.
FAQs
- Who manufactures the labeled commercial drug product for VOYDEYA in the US?
- Which companies supply the APIs for estradiol and medroxyprogesterone acetate used in VOYDEYA?
- Does VOYDEYA have multiple NDA presentations that use different manufacturing sites?
- What Orange Book patents most constrain generic manufacturing for VOYDEYA?
- How do DSCSA and packaging/labeling requirements shape VOYDEYA’s packaging supplier selection?
References
None (no citable VOYDEYA product identifiers or source documents were provided).
